SANTEN PHARMACEUTICAL CO.,LTD. Logo

SANTEN PHARMACEUTICAL CO.,LTD.

A global company specializing in pharmaceuticals and medical devices for ophthalmology.

4536 | T

Overview

Corporate Details

ISIN(s):
JP3336000009
LEI:
Country:
Japan
Address:
大阪市北区大深町4番20号

Description

Santen Pharmaceutical Co., Ltd. is a global company specializing in ophthalmology. It is engaged in the research, development, manufacturing, sales, and marketing of pharmaceutical products and medical devices dedicated to eye health. The company's portfolio includes prescription and over-the-counter pharmaceuticals that address a wide range of ophthalmic conditions. Serving patients, consumers, and medical professionals in over 60 countries, Santen aims to contribute to the realization of “Happiness with Vision” by providing valuable products and services worldwide.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-12-15 06:37
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 24.5 KB
2025-11-14 01:56
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 25.9 KB
2025-11-10 07:02
確認書
Japanese 8.7 KB
2025-11-10 07:01
半期報告書-第114期(2025/04/01-2026/03/31)
Japanese 366.6 KB
2025-10-15 03:28
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 24.2 KB
2025-09-12 04:58
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 25.9 KB
2025-08-13 03:24
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 25.8 KB
2025-07-15 04:38
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 25.2 KB
2025-06-25 04:08
臨時報告書
Japanese 26.5 KB
2025-06-24 09:22
臨時報告書
Japanese 32.1 KB
2025-06-23 08:29
内部統制報告書-第113期(2024/04/01-2025/03/31)
Japanese 24.3 KB
2025-06-23 08:28
確認書
Japanese 8.5 KB
2025-06-23 08:27
有価証券報告書-第113期(2024/04/01-2025/03/31)
Japanese 2.2 MB
2025-06-13 04:35
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 22.1 KB
2025-04-15 06:53
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 21.3 KB

Automate Your Workflow. Get a real-time feed of all SANTEN PHARMACEUTICAL CO.,LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for SANTEN PHARMACEUTICAL CO.,LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for SANTEN PHARMACEUTICAL CO.,LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.